The Myelodysplastic Syndromes (MDS) Foundation says a study published 
      this week in the Journal of Clinical Oncology concludes VIDAZA 
      (azacitidine) “prolongs survival and is well tolerated” in patients with 
      acute myeloid leukemia (AML) - an aggressive form of leukemia that in 
      many cases progresses from MDS. The study looked at older patients with 
      a median age of 70. These are patients who have had “no truly adequate 
      treatments,” however the study found that half of the patients treated 
      with VIDAZA survived at least two years, compared to only 16% of 
      patients who received conventional care. Nearly 13,000 AML patients are 
      diagnosed each year in the United States.
    
“This is encouraging news for patients with AML, an aggressive, 
      difficult to treat cancer where median survival is less than one year”
    
      “This is encouraging news for patients with AML, an aggressive, 
      difficult to treat cancer where median survival is less than one year,” 
      said Kathy Heptinstall, Operating Director of the Myelodysplastic 
      Syndromes Foundation. “Currently, as documented by an editorial in the 
      same journal, a large portion of older AML patients are offered only 
      supportive or palliative care. We would hope that publication of these 
      encouraging results will spread the word and help change the approach to 
      treatment.”
    
    
      The study also found that VIDAZA helped reduce the need for blood 
      transfusions that are often required in AML. 41% of patients on VIDAZA 
      achieved transfusion independence, compared to only 18% receiving 
      conventional care. VIDAZA treatment also significantly reduced the 
      number of days spent in the hospital, and reduced serious infections.
    
    
      The findings come from a subset of an international study of VIDAZA that 
      previously demonstrated improved survival in patients with higher-risk 
      MDS. Both MDS and AML are malignant conditions of cells in the bone 
      marrow. Previously, the National Comprehensive Cancer Network 
      recommended VIDAZA and DACOGEN® as treatment 
      options for AML patients over 60 years old.